Irvine-based Helio Genomics announces partnership with Quest Diagnostics to distribute its liver cancer detection test ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Quest's Infrastructure to Enable Access to HelioLiver(TM) , an AI-Powered, Blood-Based Test for Early Detection of Liver Cancer IRVINE, Calif., March 18, 2026 /PRNewswire/ -- Helio Genomics, an ...

Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...

Irvine, CA, USA, March 30th, 2026, FinanceWireHelio Genomics announces new HelioLiver access through Quest, expanding the ...

Secaucus, New Jersey-based Quest Diagnostics Incorporated (DGX) provides diagnostic testing and services in the United States. Valued at a market cap of $21.8 billion, the company develops and ...

Quest Diagnostics may be the preferred lab your health insurance, doctors, or specialists use for blood work or other samples. We’re reviewing its sub-brand Quest Health, from which you can order your ...

Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging ...

Gardner and Wallace will be based in Quest’s Secaucus headquarters, a company representative told NJBIZ. “These latest appointments continue to strengthen Quest’s leadership team and position us well ...

In the last three months, 7 analysts have published ratings on Quest Diagnostics (NYSE:DGX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...

Quest Diagnostics Incorporated announced its Q3 earnings yesterday - revenues year-to-date are $8.23bn, and net income $845m. DGX is finally demonstrating a strong post-pandemic recovery, with Q3 ...

Quest Diagnostics (NYSE:DGX) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion (up 15.2% year over year), organic revenue growth of 5.2%, while ...